Search

Displaying results 3631 - 3640 of 9333 in total
  1. Drug

    Xanthan gum

    go.drugbank.com/drugs/DB11253
    Approved

    The major constituents include D-glucose, D-mannose, and D-glucuronic acid. Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA.

  2. Drug

    Tagatose

    go.drugbank.com/drugs/DB04936
    Investigational

    It is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener. … Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.

  3. Drug

    Atractylodes japonica root oil

    go.drugbank.com/drugs/DB11270
    ApprovedWithdrawn

    Atractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia. … Atractylodes japonica is reported to have anti-inflammatory and antinociceptive effects [A27223].

  4. Drug

    Lauric acid

    go.drugbank.com/drugs/DB03017
    Approved

    Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses. … Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression.

  5. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    The vaccine contains *N. meningitis* serogroup a capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae … Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  6. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  7. Drug

    Sitimagene ceradenovec

    go.drugbank.com/drugs/DB04907
    Experimental

    Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy

  8. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

  9. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.

  10. Drug

    Mesterolone

    go.drugbank.com/drugs/DB13587
    Investigational

    Mesterolone demonstrated to have minimal effect on sperm counts and levels of FSH or LH [A27177, A27178].

    Categories: Sex Hormones and Modulators of the Genital System